Following on from the emergence of SGLT-2 inhibition for CKD, nsMRAs, and GLP-1 RAs have also recently demonstrated kidney and cardiovascular benefits effects in people with T2DM and CKD.11 Here, SLC5A2 is linked to type 2 diabetes mellitus.